HC Wainwright Predicts Higher Earnings for CG Oncology

CG Oncology logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its FY2028 EPS forecast for CG Oncology to a loss of $1.01 per share from $1.33, and projects earnings of $3.01 per share in FY2029 and $5.96 in FY2030. It maintains a Buy rating and a $115 price target.
  • CG Oncology reported a quarterly loss of $0.64 per share, beating the consensus estimate of a $0.83 loss; revenue of $1.60 million also exceeded expectations of $0.55 million.
  • Company insiders bought shares: CEO Arthur Kuan purchased 30,000 shares for about $2.37 million, and insider Isabel Kalofonos acquired 3,751 shares for roughly $299,000.
  • Five stocks we like better than CG Oncology.

CG Oncology, Inc. (NASDAQ:CGON - Free Report) - Stock analysts at HC Wainwright upped their FY2028 earnings per share (EPS) estimates for CG Oncology in a research report issued on Tuesday, November 17th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($1.01) per share for the year, up from their previous estimate of ($1.33). HC Wainwright currently has a "Buy" rating and a $115.00 target price on the stock. The consensus estimate for CG Oncology's current full-year earnings is ($2.97) per share. HC Wainwright also issued estimates for CG Oncology's FY2029 earnings at $3.01 EPS and FY2030 earnings at $5.96 EPS.

Several other analysts have also recently weighed in on CGON. Wall Street Zen upgraded shares of CG Oncology from a "strong sell" rating to a "sell" rating in a research report on Saturday, November 7th. Wedbush upped their target price on shares of CG Oncology from $84.00 to $91.00 and gave the stock an "outperform" rating in a research report on Tuesday. Weiss Ratings reissued a "sell (d-)" rating on shares of CG Oncology in a research note on Thursday, October 15th. JPMorgan Chase & Co. increased their target price on CG Oncology from $96.00 to $113.00 and gave the company an "overweight" rating in a research note on Tuesday. Finally, Guggenheim lowered their price target on CG Oncology from $90.00 to $89.00 and set a "buy" rating on the stock in a research report on Monday, November 9th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $98.78.

Get Our Latest Report on CG Oncology

CG Oncology Price Performance

CGON stock opened at $80.00 on Thursday. CG Oncology has a one year low of $37.01 and a one year high of $93.95. The stock has a market cap of $7.15 billion, a PE ratio of -28.99 and a beta of 0.35. The firm has a 50 day simple moving average of $68.51 and a two-hundred day simple moving average of $66.96.

CG Oncology (NASDAQ:CGON - Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.19. The company had revenue of $1.60 million for the quarter, compared to analysts' expectations of $0.55 million. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%.

Insider Buying and Selling at CG Oncology

In other CG Oncology news, CEO Arthur Kuan purchased 30,000 shares of the firm's stock in a transaction on Wednesday, November 18th. The shares were purchased at an average cost of $78.88 per share, with a total value of $2,366,400.00. Following the completion of the purchase, the chief executive officer owned 228,916 shares of the company's stock, valued at $18,056,894.08. The trade was a 15.08% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Isabel Kalofonos acquired 3,751 shares of the stock in a transaction dated Wednesday, November 18th. The stock was acquired at an average price of $79.75 per share, with a total value of $299,142.25. Following the completion of the acquisition, the insider owned 3,751 shares in the company, valued at approximately $299,142.25. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold 3,000 shares of company stock worth $227,040 over the last ninety days. Insiders own 4.80% of the company's stock.

Hedge Funds Weigh In On CG Oncology

A number of large investors have recently added to or reduced their stakes in CGON. Allspring Global Investments Holdings LLC increased its holdings in shares of CG Oncology by 4.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 3,728 shares of the company's stock worth $255,000 after buying an additional 175 shares during the period. Covestor Ltd grew its position in CG Oncology by 72.6% during the 3rd quarter. Covestor Ltd now owns 770 shares of the company's stock worth $55,000 after acquiring an additional 324 shares during the last quarter. GAMMA Investing LLC grew its position in CG Oncology by 47.9% during the 3rd quarter. GAMMA Investing LLC now owns 1,081 shares of the company's stock worth $77,000 after acquiring an additional 350 shares during the last quarter. Fiduciary Financial Advisors bought a new position in CG Oncology during the 2nd quarter worth approximately $28,000. Finally, Manchester Capital Management LLC increased its stake in CG Oncology by 2,895.5% in the 3rd quarter. Manchester Capital Management LLC now owns 659 shares of the company's stock worth $47,000 after purchasing an additional 637 shares during the period. Hedge funds and other institutional investors own 26.56% of the company's stock.

Latest CG Oncology News

Investors following CGON have been watching these news items:

  • Positive Sentiment: CEO Arthur Kuan bought 30,000 shares for about $2.37 million, increasing his holdings by 15.08%. Insider Isabel Kalofonos also purchased 3,751 shares for roughly $299,000. These purchases may signal confidence in CG Oncology’s prospects. Insider transaction details
  • Positive Sentiment: Analyst sentiment is supportive: Morgan Stanley raised its price target to $117 and maintained an Overweight rating, while HC Wainwright and Wedbush also reportedly see potential for shares to rise. HC Wainwright analyst report Wedbush analyst report
  • Negative Sentiment: Director Leonard Post sold 1,000 shares for $92,000, cutting his direct holdings by half. The sale may temper sentiment, though it is small relative to the company’s overall scale. Director sale details

CG Oncology Company Profile

(Get Free Report)

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company's research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

See Also

Earnings History and Estimates for CG Oncology (NASDAQ:CGON)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CG Oncology Right Now?

Before you consider CG Oncology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.

While CG Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines